Observational studyTranslational stroke research2020
Association of High Serum Levels of Growth Factors with Good Outcome in Ischemic Stroke: a Multicenter Study.
Observational study in Translational stroke research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Circulating brain-derived neurotrophic factor as a potential biomarker in stroke: a systematic review and meta-analysis.Journal of translational medicine · 2022Pooled it
- Serum BDNF Levels in Acute Stroke: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2021Pooled it
- Trial
- CXCL12/CXCR4 signaling governs ischemic neurovascular pathophysiology and repair: a multidimensional contextual analysis.Angiogenesis · 2026Review
- CXCL12 levels correlate with reduced stroke severity and lower risk of hemorrhagic transformation in stroke patients.Frontiers in cardiovascular medicine · 2026Article
- Observational
- Salivary chemokines and growth factors in patients with ischemic stroke.Scientific reports · 2025Article
- Prognostic Significance of Plasma VEGFA and VEGFR2 in Acute Ischemic Stroke-a Prospective Cohort Study.Molecular neurobiology · 2024Article
- The intriguing role of platelets as custodians of brain-derived neurotrophic factor.Research and practice in thrombosis and haemostasis · 2024Article
- The Secretome of Mesenchymal Stromal Cells in Treating Intracerebral Hemorrhage: The First Step to Bedside.Pharmaceutics · 2023Article
- Unraveling the potential of endothelial progenitor cells as a treatment following ischemic stroke.Frontiers in neurology · 2022Review
- The Specific Role of Reactive Astrocytes in Stroke.Frontiers in cellular neuroscience · 2022Review
- Secondary Cerebellar Cortex Injury in Albino Male Rats after MCAO: A Histological and Biochemical Study.Biomedicines · 2021Article
- Serum BDNF's Role as a Biomarker for Motor Training in the Context of AR-Based Rehabilitation after Ischemic Stroke.Brain sciences · 2020Article
- The Effect of HRE-Regulated VEGF Expression and Transfection on Neural Stem Cells in Rats.Frontiers in cell and developmental biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 1 country.
Funding
Abstract
The main objective of this research work was to study the association of serum levels of growth factors (GF) and SDF-1α with the functional outcome and reduction of lesion volume in ischemic stroke patients. In this multicenter study, 552 patients with non-lacunar stroke (male, 62.1%; mean age, 68.2 ± 11.4) were included within 24 h from symptom onset. The main outcome variable was good functional outcome (modified Rankin Scale [mRS] ≤ 2) at 12 months. Secondary outcome variable was infarct volume (in mL) after 6 ± 3 months. Serum levels of VEGF, Ang-1, G-CSF, BDNF, and SDF-1α were measured by ELISA at admission, 7 ± 1 days, at 3 ± 1 months, and 12 ± 3 months. Except for BDNF, all GF and SDF-1α serum levels showed a peak value at day 7 and remained elevated during the first 3 months (all p < 0.01). High serum levels at day 7 of VEGF (OR, 19.3), Ang-1 (OR, 14.7), G-CSF (OR, 9.6), and SDF-1α (OR, 28.5) were independently associated with good outcome at 12 months (all p < 0.0001). On the other hand, serum levels of VEGF (B, - 21.4), G-CSF (B, - 14.0), Ang-1 (B, - 13.3), and SDF-1α (B, - 44.6) measured at day 7 were independently associated with lesion volume at 6 months (p < 0.01). In summary, high serum levels of VEGF, Ang-1, G-CSF, and SDF-1α at day 7 and 3 months after ischemic stroke are associated with good functional outcome and smaller residual lesion at 1 year of follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.